Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas
- 15 May 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (10) , 3490-3499
- https://doi.org/10.1158/1078-0432.ccr-0960-03
Abstract
Purpose: Conventional staging procedures are often unable to precisely predict prognosis in colorectal cancer (CRC). In this study, we set out to investigate the possible role of molecular/structural indicators involved in cell cycle regulation (p27 and p53), apoptosis (p53 and p27), and tumor neoangiogenesis [p53, vascular endothelial growth factor (VEGF), and microvessel count] in predicting tumor behavior and clinical outcome in CRC patients Experimental Design: Analysis of the above indicators was performed by immunohistochemistry on 104 CRC patient samples and 25 normal colon mucosa specimens. Results: Intense p27 nuclear staining was found in normal colon mucosa, with p53 nuclear staining and VEGF cytoplasmic accumulation <10%, and low microvessel count. In contrast, in CRC samples, p27 was down-regulated in 53.8%, p53 protein was overexpressed in 52%, and VEGF stained positive in 67.3% of the cases, respectively. Multiple regression analysis showed that molecular markers were strongly correlated. In patients treated with curative surgery, a significant relationship was seen between p27 down-regulation and Dukes’ stage, nodal status, and the presence of distant metastases. VEGF overexpression correlated significantly with Dukes’ stage, tumor (t) and metastasis (m) parameters, and left site. Stepwise regression selected p27, p53, VEGF, and Dukes’ stage as the best combination of variables capable of predicting both disease-specific and disease-free survival. Conclusions: The investigated indicators may be useful for the prediction of outcome and recurrence rate in curatively treated CRC patients. In conjunction with clinical and pathological staging, they may provide a stronger indication of clinical outcome than staging alone and help better select therapeutic options in CRC patients.Keywords
This publication has 27 references indexed in Scilit:
- Clinical utility of biochemical markers in colorectal cancerEuropean Journal Of Cancer, 2003
- Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes’ B and C Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative StudyJournal of Clinical Oncology, 2003
- New Strategies for Colorectal Cancer Prevention and TreatmentWorld Journal of Surgery, 2002
- Havep53gene mutations and protein expression a different biological significance in colorectal cancer?*Journal of Cellular Physiology, 2002
- The results of colorectal cancer treatment by p53 statusDiseases of the Colon & Rectum, 2001
- Should Dukes' B patients receive adjuvant therapy? A statistical perspectiveSeminars in Oncology, 2001
- Down-Regulation of p27 Is Associated with Development of Colorectal Adenocarcinoma MetastasesThe American Journal of Pathology, 1998
- Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasisInternational Journal of Cancer, 1997
- Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancerHistopathology, 1996
- Genetic Alterations during Colorectal-Tumor DevelopmentNew England Journal of Medicine, 1988